Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations
Abstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverg...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-06-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-021-00190-3 |
| _version_ | 1797643047683489792 |
|---|---|
| author | S. Vasudevan E. Flashner-Abramson Heba Alkhatib Sangita Roy Chowdhury I. A. Adejumobi D. Vilenski S. Stefansky A. M. Rubinstein N. Kravchenko-Balasha |
| author_facet | S. Vasudevan E. Flashner-Abramson Heba Alkhatib Sangita Roy Chowdhury I. A. Adejumobi D. Vilenski S. Stefansky A. M. Rubinstein N. Kravchenko-Balasha |
| author_sort | S. Vasudevan |
| collection | DOAJ |
| description | Abstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverge and become supported by various signaling networks. Therefore, patient-specific altered signaling signatures should be deciphered and treated individually. In this study, we design individualized melanoma combination treatments based on personalized network alterations. Using an information-theoretic approach, we compute high-resolution patient-specific altered signaling signatures. These altered signaling signatures each consist of several co-expressed subnetworks, which should all be targeted to optimally inhibit the entire altered signaling flux. Based on these data, we design smart, personalized drug combinations, often consisting of FDA-approved drugs. We validate our approach in vitro and in vivo showing that individualized drug combinations that are rationally based on patient-specific altered signaling signatures are more efficient than the clinically used anti-BRAFV600E or BRAFV600E/MEK targeted therapy. Furthermore, these drug combinations are highly selective, as a drug combination efficient for one BRAFV600E tumor is significantly less efficient for another, and vice versa. The approach presented herein can be broadly applicable to aid clinicians to rationally design patient-specific anti-melanoma drug combinations. |
| first_indexed | 2024-03-11T14:09:01Z |
| format | Article |
| id | doaj.art-3fa3ce4bd8c843c780d29b16c0e89e36 |
| institution | Directory Open Access Journal |
| issn | 2397-768X |
| language | English |
| last_indexed | 2024-03-11T14:09:01Z |
| publishDate | 2021-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj.art-3fa3ce4bd8c843c780d29b16c0e89e362023-11-02T00:43:00ZengNature Portfolionpj Precision Oncology2397-768X2021-06-015111310.1038/s41698-021-00190-3Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterationsS. Vasudevan0E. Flashner-Abramson1Heba Alkhatib2Sangita Roy Chowdhury3I. A. Adejumobi4D. Vilenski5S. Stefansky6A. M. Rubinstein7N. Kravchenko-Balasha8The Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemThe Institute of Biomedical and Oral Research, Hebrew University of JerusalemAbstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverge and become supported by various signaling networks. Therefore, patient-specific altered signaling signatures should be deciphered and treated individually. In this study, we design individualized melanoma combination treatments based on personalized network alterations. Using an information-theoretic approach, we compute high-resolution patient-specific altered signaling signatures. These altered signaling signatures each consist of several co-expressed subnetworks, which should all be targeted to optimally inhibit the entire altered signaling flux. Based on these data, we design smart, personalized drug combinations, often consisting of FDA-approved drugs. We validate our approach in vitro and in vivo showing that individualized drug combinations that are rationally based on patient-specific altered signaling signatures are more efficient than the clinically used anti-BRAFV600E or BRAFV600E/MEK targeted therapy. Furthermore, these drug combinations are highly selective, as a drug combination efficient for one BRAFV600E tumor is significantly less efficient for another, and vice versa. The approach presented herein can be broadly applicable to aid clinicians to rationally design patient-specific anti-melanoma drug combinations.https://doi.org/10.1038/s41698-021-00190-3 |
| spellingShingle | S. Vasudevan E. Flashner-Abramson Heba Alkhatib Sangita Roy Chowdhury I. A. Adejumobi D. Vilenski S. Stefansky A. M. Rubinstein N. Kravchenko-Balasha Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations npj Precision Oncology |
| title | Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations |
| title_full | Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations |
| title_fullStr | Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations |
| title_full_unstemmed | Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations |
| title_short | Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations |
| title_sort | overcoming resistance to brafv600e inhibition in melanoma by deciphering and targeting personalized protein network alterations |
| url | https://doi.org/10.1038/s41698-021-00190-3 |
| work_keys_str_mv | AT svasudevan overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT eflashnerabramson overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT hebaalkhatib overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT sangitaroychowdhury overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT iaadejumobi overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT dvilenski overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT sstefansky overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT amrubinstein overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations AT nkravchenkobalasha overcomingresistancetobrafv600einhibitioninmelanomabydecipheringandtargetingpersonalizedproteinnetworkalterations |